Skip To Main Content
Lara McGrath on Muck Rack

Lara McGrath

As seen in: Nature

Get in touch with Lara

Contact Lara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial - Nature Medicine

|
By Tina Cascone, Laura Bonanno, Florian Guisier, Amelia Insa, Moishe Liberman, Olivier Bylicki, Lorenzo Livi, Thomas Egenod, Romain Corre, Dong-Wan Kim, Mariano Provencio Pulla, Byoung Yong Shim, Agata A. Bielska, Alula Yohannes, Yun He, Adam Dowson, Gozde Kar, Lara McGrath, Rakesh Kumar, Italia Grenga, Jonathan Spicer Verified
| Nature Verified
Abstract In the phase II NeoCOAST-2 platform study, 202 patients with untreated, resectable stage IIA–IIIB non-small-cell lung cancer (NSCLC) were randomized to receive neoadjuvant durvalumab plus platinum-doublet chemotherapy with oleclumab, a CD73 inhibitor (Arm 1), or with monalizumab, a NKG2A inhibitor (Arm 2), or neoadjuvant durvalumab plus single-agent platinum chemotherapy with the TROP-2 antibody–drug conjugate (ADC) datopotamab deruxtecan (Arm 4), followed by surgical resection and...
Open in Who Shared Issue with article?
See all 1 licensed articles (2 Total)